GoKawiilHershey CEO Kirk Tanner says GLP-1 drugs aren't hurting candy sales
In an interview, Hershey CEO Kirk Tanner said weight-loss drugs like Ozempic are not damaging the company's candy business, and in some cases benefit it. He also described how Hershey now uses artificial intelligence to direct its sales force in real time at retailers like Target and Walmart, as part of efforts to keep the brand culturally relevant.
GoKawiil's interpretation of the reporting above, not reported fact.
Tanner's comments push back on investor worries that GLP-1 drugs could permanently dent demand for sugary snacks, a concern that has weighed on confectionery and packaged-food stocks. His description of AI-guided sales routing suggests Hershey is leaning on data tools to sharpen retail execution, which could shape how other legacy consumer brands respond to similar pressures.
- Hershey CEO says GLP-1 weight-loss drug users aren't hurting candy sales
- Hershey is using AI to direct its sales force in real time at retailers like Target and Walmart
- Tanner frames staying culturally relevant as a key priority for the brand
Hershey's Milk Chocolate Candy Bars — Since the article centers on Hershey's iconic brand and its enduring cultural relevance, why not stock up on the classic candy bar that started it all? It's a nostalgic treat that pairs perfectly with the story's discussion of keeping an American icon fresh and beloved.
See Hershey's Milk Chocolate Candy Bars on Amazon → Affiliate link — we may earn a commission on purchases, at no extra cost to you. Product picked by AI based on this article; it is not a tested recommendation.Source: fastcompany.com, 2026-10-01
Published there as: “Hershey CEO Kirk Tanner on GLP-1s, AI, and keeping an iconic brand relevant”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.